New research published in Nature Cancer has identified iron accumulation as a trigger for the destruction of CAR-T immune cells. We explore what this unexpected finding could mean for the future of lung cancer treatment.

RET fusions drive around 1 to 2% of all lung cancers. For years, treatment options were limited. That has changed. New data from ASCO 2026 show that targeted therapies now span multiple stages of RET fusion-positive lung cancer, with next-generation options already in development. Lung Cancer Europe explains the science, the treatments, and what to ask your oncologist.